



Session Details

Session # 204

Title: Treatment of Heart Failure for the PCP

Speaker: Mark Puhlman, DNP, ANP-C

Date: 10/6/2017

Time: 10 AM

CE Contact Hours: 1.25

Pharm Hours: 1.08

Session Description

The presentation will be a discussion of the heart failure guidelines as set forth in the American Heart Association Updated Guidelines (Yancey, 2013) and the National Guideline Clearinghouse (guideline.gov, 2015) maintained by the U.S. Department of Health and Human Services. The presentation will review the pathophysiology of heart failure, and the initial work-up of the new patient. It will review the initial testing that is required and how to refer/work in concert with the cardiologist for the initial diagnosis and screening of reversible causes. The presentation will discuss the care of the chronic heart failure patient after the patient has been sent back to the provider for chronic management. This will include chronic drug management, pharmacology of the routine management drugs and patient teaching required to care for a chronic disease. It also will focus on the family support that is required to care for the heart failure patient long term. It will then discuss the advanced care options for patients with advanced heart failure and the indicators that the patient may exhibit to call for referral back to the advanced heart failure program for consideration for those advanced therapies. Finally, if the patient is unable to obtain a transplant or LVAD due to co-morbidities, the patient may be sent back to the PCP for management in Palliative Care including Palliative chronic IV inotrope therapy. The needs of the patient dying with heart failure will be addressed.

Learning Objectives

Upon completion of this session, the learner will be able to:

1. Name three standard heart failure medications, their pharmacology and their starting doses.
2. Describe the pathophysiology of heart failure.
3. Name the criteria for up-titration and down titration of ACE inhibitors and Beta Blockers.
4. Describe the three advanced heart failure therapies and the criteria for these therapies.

Disclosures

Conflict of Interest for Presenter:

- The presenter(s) of this session declare no conflict of interest. As faculty/presenter for this activity, presenter attests that they will provide the best available evidence for this content and present information fairly and without bias.